Shenzhen Synbio Technologies Files IPO Prospectus as Award-Winning LVV Solutions Provider at CSGCT Conference

Shenzhen Shenyan Biotechnology Co., Ltd.

Abbreviation: Shenyan Bio

Shenyan Biotech is a core upstream supplier in the field of cell and gene therapy, focusing on the independent research and development of core technologies and equipment in the CGT sector.

Committed to discovering innovative pathways in the life sciences through interdisciplinary integration and technological innovation involving computer science, electronic engineering, nanomaterials, chemical engineering, and other fields with life sciences, we aim to progressively address a series of key technical challenges in gene therapy, cell therapy, and life science and pharmaceutical R&D, continuously expanding the frontiers of treatment.

The EuLV®️ system is a lentiviral vector production platform based on stable cell lines. It utilizes inducible stable producer cell lines to manufacture lentiviral vectors through high-cell-density suspension culture in chemically defined media (CDM).

The EuLV®️ Stable Production System will become the ideal choice for large-scale LVV production in the in vivo field, with the following key advantages:

● Higher-quality viral vectors: Viral titers are 50-fold higher than those achieved by transient transfection (reaching 9×10⁷ TU/mL), with higher specific activity of the vector and more stable transduction efficiency; certain clones demonstrate superior transduction performance in naïve T cells.

● Exclusive stable production cell line platform: A high-throughput monoclonal SPCL screening platform developed based on synthetic biology, ensuring efficient selection of high-quality cell lines.

● Scalable vector production process: Serum-free suspension culture process, easier to scale up

To drive technological breakthroughs, industrial integration, policy alignment, and international cooperation in China’s cell and gene therapy (CGT) sector, and to propel the Chinese CGT industry to the forefront of global competition, the China Society for Cell and Gene Therapy (CSGCT) Conference was established.

Leveraging its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Conference will bring together leading scientists, clinical experts, multinational pharmaceutical companies, and overseas investment institutions from around the world. The event will showcase the most cutting-edge scientific advances, technologies, and applications in the global cell and gene therapy field, provide insights on market access, highlight high-quality collaborative projects, and facilitate matchmaking between overseas investors and investment opportunities. It aims to build a platform for in-depth exchange and cooperation between China’s cell and gene therapy industry and the global industrial chain.

The conference closely addressed the industry’s hotspots, pain points, and bottlenecks, featuring1 Main Forum + 15 High-End Sub-forums, coveringLatest Advances in Global Gene Therapy, Immune Cell Therapy, In Vivo CAR-T, Adult Stem Cells and Exosomes, iPSC-Derived Cell Therapies, Small Nucleic Acid Drugs, Gene Editing, Oncolytic Viruses, and Tumor Vaccines, as Well as CMC and Testing, AI-Driven Drug R&D, Investment and Financing, and BD Matchmaking...with in-depth coverage across the entire industry chain.

2025 The 2nd China Society for Gene and Cell Therapy (CSGCT) Conference

September 12-13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, scan the QR code to visit the official conference website.